TITLE

Decidual Stromal Cells from Placenta - Experimental and Clinical Studies

AUTHOR(S)
Ringdén, O.; Kaipe, H.; Erkers, T.; Nava, S.; Molldén, P.; Sadeghi, B.
PUB. DATE
June 2013
SOURCE
Cell Journal (Yakhteh);Summer 2013 Supplement 1, Vol. 15 Issue Sup 1, p13
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Objective: One of the most serious complications after hematopoietic stem cell transplantation is acute graftversus- host disease (GVHD), which develops when donor- derived T-cells recognize and become activated by alloreactive recipient tissue. We were the first to use bone marrow-derived mesenchymal stem cells (BM-MSCs) to reverse severe steroid-refractory acute GVHD and hemorrhagic cystitis. The fetus is protected against the mother's immune system by the fetal membrane. We wanted to explore if stromal cells from the placenta could be used for GVHD and tissue damage in a similar way as MSCs. Materials and Methods: We collected stromal cells from various parts of the placenta. To characterize these cells, we used fluorescence activated cell sorter (FACS). For functional analysis, mixed lymphocyte culture (MLC) and mitogen stimulation of human and mice cells were used. For studies of GVHD, we used B6 mice as donors and Balb/C mice as recipients of hematopoietic stem cell transplants. Patients with steroidrefractory acute GVHD were also included. Results: Stromal cells from the fetal membrane were easy to expand in vitro. We found that decidual stromal cells (DSCs) had the best immunosuppressive effect in vitro in MLC. Caryotyping of DSCs showed normal female karyotype. PCR showed that these cells were of female, maternal type. DCSs were positive for typical MSC markers, CD29, CD44, CD73, CD90 and CD105. DSCs were negative for hematopoietic markers, endothelial markers and epithelial markers. Unlike BM-MSCs, they were positive for PD-L1 and PD-L2 (negative regulation of co-stimulatory molecules). DSCs were also positive for CD49D, a marker for homing to inflammatory tissue (integrin). Indoleamine2,3-deoxygenase, prostaglandin E2, PD-L1 and interferon- • seemed to participate in the immunosuppressive mechanism by DSCs. DSCs promote CD4+ CD25+ FoxP3+ regulatory T-cell expansion in a contactdependent manner. Human DSCs inhibit mice MLC and also mice cells stimulated by phytohemaggluthinin. Human DSCs also inhibited mice cells stimulated by human blood lymphocytes. For Balb/C mice undergoing stem cell transplantation with B6 donors, GVHD was reduced if DSCs were added on day 3 after transplantation. Human DSCs also stimulated proliferation in xeno-immunized mice, but could also depress this reactivity in vitro. Among eight evaluable patients with severe steroid-refractory acute GVHD, two had a complete response, four had a partial response with an overall response rate of 75%. Two patients did not respond at all. Melena stopped in three patients with severe hemorrhagic diarrhea after treatment with DSCs. Among the patients treated with DSCs, three are long-term survivors. Conclusion: Stromal cells from the fetal membrane inhibit alloreactivity in vitro in MLC. They are of maternal origin, are safe to infuse to patients and they can inhibit and resolve GVHD in experimental animals and in patients. DSC therapy needs to be improved.
ACCESSION #
93362831

 

Related Articles

  • Allogeneic clonal mesenchymal stem cell therapy for refractory graft-versus-host disease to standard treatment: a phase I study. Hyeon Gyu Yi; Seung-Ah Yahng; Inho Kim; Je-Hwan Lee; Chang-Ki Min; Jun Hyung Kim; Chul Soo Kim; Sun U. Song // Korean Journal of Physiology & Pharmacology;2016, Vol. 20 Issue 1, p63 

    Severe graft-versus-host disease (GVHD) is an often lethal complication of allogeneic hematopoietic stem cell transplantation (HSCT). The safety of clinicalgrade mesenchymal stem cells (MSCs) has been validated, but mixed results have been obtained due to heterogeneity of the MSCs. In this phase...

  • Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Peng, Y; Chen, X; Liu, Q; Zhang, X; Huang, K; Liu, L; Li, H; Zhou, M; Huang, F; Fan, Z; Sun, J; Ke, M; Li, X; Zhang, Q; Xiang, A P // Leukemia (08876924);Mar2015, Vol. 29 Issue 3, p636 

    Refractory chronic graft-versus-host disease (cGVHD) is a significant complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). Mesenchymal stromal cells (MSCs) have shown promise for treating refractory cGVHD, but the favorable effects of MSCs therapy in cGVHD are...

  • Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Kim, Nayoun; Im, Keon-Il; Lim, Jung-Yeon; Jeon, Eun-Joo; Nam, Young-Sun; Kim, Eun-Jung; Cho, Seok-Goo // Annals of Hematology;Oct2013, Vol. 92 Issue 10, p1295 

    Mesenchymal stem cells (MSCs) have emerged as a therapeutic approach in a range of medical fields, including regenerative medicine, cancer, autoimmune diseases, and inflammatory diseases, because of their unique properties of tissue repair and major histocompatibility complex-unmatched...

  • AlloCure Raises $25 Mln Series B Venture Financing.  // Biomedical Market Newsletter;4/7/2012, Vol. 21, p1 

    The article discusses the closing of a 25 million dollars series B venture financing by the AlloCure Inc. It states that the managing partner of Lundbeckfond Ventures Mette Kirstine Agger has joined the Allocure board of directors. It further informs that the company is working on developing an...

  • Biomarker may detect GVHD of the gastrointestinal tract after HSCT.  // Hem/Onc Today;11/25/2011, Vol. 12 Issue 22, p31 

    The article presents a study that deals with a plasma biomarker that can help physicians identify patients with cancer who are at the greater risk for graft-versus-host disease after hematopoietic stem cell transplantation.

  • Characterization and ex vivo expansion of human placenta-derived natural killer cells for cancer immunotherapy. Lin Kang; Voskinarian-Berse, Vanessa; Law, Eric; Reddin, Tiffany; Bhatia, Mohit; Hariri, Alexandra; Yuhong Ning; Dong, David; Maguire, Timothy; Yarmush, Martin; Hofgartner, Wolfgang; Abbot, Stewart; Xiaokui Zhang; Hariri, Robert // Frontiers in Immunology;May2013, Vol. 4, p1 

    Recent clinical studies suggest that adoptive transfer of donor-derived natural killer (NK) cells may improve clinical outcome in hematological malignancies and some solid tumors by direct anti-tumor effects as well as by reduction of graft versus host disease (GVHD). NK cells have also been...

  • Mechanisms of T cell tolerance towards the allogeneic fetus. Erlebacher, Adrian // Nature Reviews Immunology;Jan2013, Vol. 13 Issue 1, p23 

    Work on the mechanisms of fetomaternal tolerance has undergone a renaissance in recent years, and the general outlines of a solution to this long-standing paradox of 'transplantation' immunology have come into view. Here, we discuss several mechanisms, recently described in mice, that either...

  • Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. Atsuta, Y.; Suzuki, R.; Yamamoto, K.; Terakura, S.; Iida, H.; Kohno, A.; Naoe, T.; Yano, K.; Wakita, A.; Taji, H.; Hamaguchi, M.; Kodera, Y.; Sao, H.; Morishima, Y.; Hamajima, N.; Morishita, Y. // Bone Marrow Transplantation;Feb2006, Vol. 37 Issue 3, p289 

    The incidence and prognostic factors for chronic graft-versus-host disease (cGVHD) were evaluated for 255 Japanese patients who survived more than 100 days after bone marrow transplantation, and of whom 119 (47%) developed cGVHD. Prior acute GVHD (grade 2–4) and use of an unrelated donor...

  • Prevalence and risk factors associated with development of ocular GVHD defined by NIH consensus criteria. Jacobs, R; Tran, U; Chen, H; Kassim, A; Engelhardt, B G; Greer, J P; Goodman, S G; Clifton, C; Lucid, C; Vaughan, L A; Savani, B N; Jagasia, M // Bone Marrow Transplantation;Nov2012, Vol. 47 Issue 11, p1470 

    We studied 172 patients for development of ocular graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from 2002 to 2009. Ocular GVHD was diagnosed in 60 patients (38%), with 27 (16%) being diagnosed at days 100 and 33 (23%) beyond day 100 for a 2-year...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics